Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković · 1996 · Neoplasma. 43(4):245–252
What does this source report?
NK-cell measurements increased with T-activin, including in patients whose disease progressed. Disease-free intervals were similar; the reported survival difference was not statistically significant.
- Population and setting
- 17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
- Evidence type
- Human comparative study
- Preparation
- T-activin thymus preparation
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Very small adjunctive comparison; random allocation and blinding are not established by the abstract.
- Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Journal article
Review depth: Indexed abstract reviewed
Source access and review scope
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. Neoplasma. 43(4):245–252 1996.
Molekul research summary: https://molekul.io/research/gaps-tactivin-8931749. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry